This Article  • References  • Full text PDF  • Reply to article  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citation map  • Citing articles on HighWire  • Citing articles on Web of Science (7)  • Contact me when this article is cited  Related Content  • Similar articles in this journal  Social Bookmarking   What's this?

Susan B. Bressler, MD

Arch Ophthalmol. 1993;111(2):177-180.

	Since this article does not have an abstract, we have provided the first 150 words of the full text PDF and any section headings.

During the last two decades laser treatments have been shown to be effective in reducing the risk of visual loss in diabetic retinopathy,^1-3 age-related macular degeneration (AMD),^4-7 and branch retinal vein occlusions.^8,9 While the number of successful clinical trials proliferated and the benefits of laser therapy in retinal and choroidal diseases became increasingly well established, there was a parallel explosion in technologic advances that simultaneously introduced a variety of newer lasers into the market. New instrumentation has yielded lasers that can produce wavelengths from blue-green to green to yellow and to red, each at the touch of a button. Each technological advance in the "rainbow" came with theoretical advantages, but will new technology improve efficacy of treatment? Only recently have clinical trials provided the opportunity to expand the evaluation of these various wavelengths from the theoretical realm to a more practical arena.

HISTORICAL PERSPECTIVES

One of . . . [Full Text PDF of this Article]

Author Affiliations
Baltimore, Md

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?